A 62-year-old woman with squamous cell carcinoma of the lung presents with hypercalcemia (Ca2+ 12.5 mg/dL), elevated PTHrP (parathyroid hormone-related peptide), and low serum phosphate. Which feature best distinguishes PTHrP-mediated hypercalcemia from osteolytic hypercalcemia in paraneoplastic syndrome?

Explanation

## PTHrP-Mediated vs. Osteolytic Hypercalcemia in Malignancy **Key Point:** Both paraneoplastic hypercalcemia mechanisms present with elevated serum calcium, but the **presence and pattern of bone metastases** is the best discriminating feature. ### Comparison Table | Feature | PTHrP-Mediated | Osteolytic | |---------|---|---| | **Mechanism** | Tumor secretes PTHrP | Tumor-adjacent osteoclast activation (IL-6, TNF-α, RANKL) | | **Bone Metastases** | Absent or minimal | Present and extensive | | **Serum Phosphate** | Low (PTHrP ↓ renal reabsorption) | Normal or high | | **Serum 1,25-OH Vitamin D** | Low (PTHrP suppresses 1α-hydroxylase) | Normal or low | | **Urinary cAMP** | Elevated (PTHrP mimics PTH) | Normal | | **Common Malignancies** | Squamous lung, kidney, breast, ovary | Lymphoma, myeloma, breast | | **Imaging Finding** | No lytic lesions | Lytic bone lesions | **High-Yield:** **Osteolytic hypercalcemia requires visible bone metastases on imaging (X-ray, CT, or bone scan)**. PTHrP-mediated hypercalcemia occurs WITHOUT bone metastases—the tumor secretes a humoral factor that acts systemically on the kidney and bone. **Clinical Pearl:** Squamous cell lung cancer (as in this case) is the classic cause of PTHrP-mediated hypercalcemia. Lymphoma and myeloma are classic causes of osteolytic hypercalcemia with extensive bone involvement. **Mnemonic:** **PTHrP = Peptide (humoral, no mets needed)**; **Osteolytic = Osteoclasts (require bone mets).** ### Pathophysiology Distinction ```mermaid flowchart TD A[Paraneoplastic Hypercalcemia]:::outcome --> B{Bone Metastases Present?}:::decision B -->|No or minimal| C[PTHrP-Mediated]:::outcome C --> D[Tumor secretes PTHrP]:::action D --> E[↓ Renal phosphate reabsorption]:::action E --> F[↓ Serum phosphate, ↑ Ca2+]:::outcome B -->|Yes, extensive| G[Osteolytic]:::outcome G --> H[Tumor cytokines activate osteoclasts]:::action H --> I[Bone resorption, ↑ Ca2+]:::outcome ``` **Why This Matters:** The distinction guides imaging and treatment: - **PTHrP-mediated:** Treat tumor + bisphosphonates; imaging shows no lytic lesions - **Osteolytic:** Treat bone disease + systemic therapy; imaging shows lytic lesions [cite:Robbins 10e Ch 7; Harrison 21e Ch 297]